ライフサイエンスコーパス: interatrial

1 y, and volume of epicardial, periatrial, and interatrial adipose tissue.

2 In each heart, the interatrial and internodal pathways were similarly invol

3 d left atria, right and left ventricles, and interatrial and interventricular septa.

4 pling interval, from the right atrium to the interatrial area and finally to the left atrium.

5 Interatrial block (IAB) is an electrocardiographic patte

6 ave duration, abnormal P-wave axis, advanced interatrial block, and abnormal P-wave terminal force in

7 2+/-0.6 kg; P=0.453), presence of a baseline interatrial communication (66% versus 61%; P=0.659), int

8 bility of fetal catheterization to create an interatrial communication and describes technical consid

9 with significant increase in the size of the interatrial communication and fossa ovalis, and decrease

10 gent catheterization to create or enlarge an interatrial communication before surgical palliation.

11 The patent foramen ovale (PFO) is a normal interatrial communication during fetal life that persist

12 ial communication (66% versus 61%; P=0.659), interatrial communication gradient (14.4+/-6.9 versus 12

13 (HLHS) have been correlated with restrictive interatrial communication or intact atrial septum (RAS)

14 tients underwent transcatheter closure of an interatrial communication using the CardioSEAL (n = 22),

15 e absence of ductal stent, older age, absent interatrial communication, smaller aortic root size, lar

16 c defect resulting in a small but persistent interatrial communication.

17 d with a matched control group with adequate interatrial communication.

18 ormal other than for the demonstration of an interatrial communication.

19 Interatrial communications may play a role in the etiolo

20 ew is to provide a comprehensive overview of interatrial communications with an intact atrial septum,

21 e been reported in hundreds of patients with interatrial communications, patent ductus arteriosus, an

22 n 12% of adults and has been associated with interatrial communications.

23 e (BB) is considered to be the main route of interatrial conduction and to play a role in development

24 malities, 68 had atrial fibrillation (AF) or interatrial conduction block (IAB) (P wave duration, >or

25 Pathologic analysis revealed that complete interatrial conduction block was associated with conflue

26 Recent data suggest that interatrial conduction can be important in triggering an

27 arization (Ta-TcD) are believed to represent interatrial conduction defect.

28 he slower atria after ablation close to main interatrial conduction fascicles (P=0.035).

29 Therefore, a method for attenuating interatrial conduction may have therapeutic value.

30 Interatrial conduction occurs in specific zones.

31 ught to characterize a method of attenuating interatrial conduction using radiofrequency ablated lesi

32 Cx40 plays an essential role in establishing interatrial conduction velocity heterogeneity in the mur

33 In 13 healthy pigs, interatrial conduction was evaluated before and after se

34 After ablation of zone 1, interatrial conduction was slowed, but there was no bloc

35 lation of the right atrial septum attenuated interatrial conduction without disturbing atrioventricul

36 lation of the right atrial septum, targeting interatrial conduction zones.

37 frequency domain analysis of a wide bipolar interatrial electrogram describes the global organizatio

38 An interatrial fenestration is designed to maintain cardiac

39 In patients with potential for interatrial flow, this may lead to a right-to-left shunt

40 onfidence interval, 6.1-6.23; P=0.021), with interatrial frequency gradients established by the spati

41 scent at E7.5, and in the outflow tract, the interatrial groove, the atrioventricular canal and right

42 treatment of patients with different cardiac interatrial morphologies or pathologies who have had str

43 TAPVR, PDA, cardiac apex and heart chambers, interatrial or interventricular septal defects, pericard

44 pEF-PH: 1.3+/-0.2 versus PAH: 1.2+/-0.1) and interatrial pressure gradient (9 [5 to 12] versus 2 [-2

45 (HFpEF-PH: 1.3 0.2 versus PAH: 1.2 0.1) and interatrial pressure gradient (9 [5 to 12] versus 2 [-2

46 syndrome patients subdivided into those with interatrial (pretricuspid) versus interventricular or gr

47 PFOs associated with an interatrial septal aneurysm seem to be more strongly lin

48 s by the coronary sinus (Lat-PAC; n=10), (2) interatrial septal PACs (Sep-PAC; n=10), (3) regular LA

49 One year after interatrial septal shunt device implantation, there were

50 rved ejection fraction patients 1 year after interatrial septal shunt device implantation.

51 nary analyses have demonstrated that a novel interatrial septal shunt device that allows shunting to

52 participated in the open-label study of the interatrial septal shunt device.

53 ; wall thickness (r=-0.54 to -0.63, P<0.04); interatrial septal thickness (r=-0.52, P=0.001); and dia

54 sisting of a bridge (suture) element between interatrial septal wall and great cardiac vein anchors.

55 o 91% for all scallops of both MV leaflets), interatrial septum (84%), left atrial appendage (86%), a

56 regions of the adult heart: clusters in the interatrial septum and around the pulmonary veins, scatt

57 Among these were the embryogenesis of the interatrial septum and development of anatomic variants

58 Two thrombi became wedged in the interatrial septum and incompletely withdrawn into the R

59 thickening of the mitral valve leaflets, and interatrial septum and mild pericardial effusion.

60 Virtual Catalytic Conference on the Cardiac Interatrial Septum and Stroke Risk, held on December 7,

61 measurements of enhancement thickness at the interatrial septum and the number of days after ablation

62 There is emerging evidence that the cardiac interatrial septum has an important role as a thromboemb

63 ivation of the right and left aspects of the interatrial septum is discordant.

64 Targeting specific sites of the interatrial septum is followed by an increase in heart r

65 and left atrium in the presence of an intact interatrial septum is possible, although uncommon.

66 ber architecture of right and left atria and interatrial septum provide a means of investigating the

67 neuroablation was performed in both atria by interatrial septum puncture, with irrigated conventional

68 foramen ovale (PFO) describes a valve in the interatrial septum that permits shunting of blood or thr

69 ntegrated backscatter image sequences of the interatrial septum to internally calibrate the left vent

70 of the patients) or right side (36%) of the interatrial septum was observed to be responsible for >/

71 ated Langendorff-perfused rabbit hearts, the interatrial septum was perforated to equalize biatrial p

72 this conference, many aspects of the cardiac interatrial septum were discussed.

73 l valve (MV), aortic valve, tricuspid valve, interatrial septum, and left atrial appendage were obtai

74 ght atrium, pacing from novel sites like the interatrial septum, Bachman bundle, and dual-site or bia

75 ardiomyopathy, lipomatous hypertrophy of the interatrial septum, cardiac lipomas and liposarcomas) co

76 arly along the right and left aspects of the interatrial septum, is not clear.

77 both atria, but were mainly confined to the interatrial septum, pulmonary veins, roof of left atrium

78 corresponded to the expected position of the interatrial septum.

79 soft tissue along the right atrial wall and interatrial septum.

80 We aimed to investigate whether an interatrial shunt can reduce heart failure events or imp

81 ejection fraction suggests that a no-implant interatrial shunt can significantly improve the pressure

82 n experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early

83 timeframe some HFpEF patients had undergone interatrial shunt device (IASD) implantation.

84 Implantation of an interatrial shunt device (IASD) in patients with heart f

85 domized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was asso

86 he performance and safety of a transcatheter interatrial shunt device (IASD, Corvia Medical, Tewkesbu

87 A novel transcatheter interatrial shunt device has been developed and evaluate

88 he rationale for a therapeutic transcatheter interatrial shunt device in HFpEF, and we describe the d

89 Implantation of an interatrial shunt device is feasible, seems to be safe,

90 Placement of an interatrial shunt device reduces pulmonary capillary wed

91 Transcatheter interatrial shunt implantation was safe but did not impr

92 e of MHA and assessed whether closure of the interatrial shunt in patients with MHA would result in i

93 An interatrial shunt may provide an autoregulatory mechanis

94 ed to indicate the presence of a significant interatrial shunt that was eventually detected following

95 hesized that the creation of a left-to-right interatrial shunt to decompress the left atrium (without

96 re randomized at 94 sites in 11 countries to interatrial shunt treatment (n=250) or a placebo procedu

97 Closure of left-to-right interatrial shunt without causing pulmonary vein occlusi

98 gible patients with closure of left-to-right interatrial shunt without pulmonary vein occlusion under

99 n associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was low

100 n associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus lon

101 e, before and after creation of a no-implant interatrial shunt.

102 er, transeptal creation of a 7 mm no-implant interatrial shunt.

103 ential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with

104 The impact of no-implant interatrial shunting on atrial structure and function ha

105 t superior vena cava (SVC) is a rare form of interatrial shunting that can have substantial clinical

106 y considering the physiologic effects during interatrial shunting.

107 basis of clinical experience with congenital interatrial shunts in mitral stenosis, it has been hypot

108 o determine whether transcatheter closure of interatrial shunts is an effective treatment for MHA.

109 .2 years), of whom 81% had moderate or large interatrial shunts.

110 prevention of adverse cardiac remodelling by interatrial shunts; and finally targeting the myocardium